On May 6, 2021 (BJT), NHT210118 Project Kick-off Meeting was held at the leading organization - Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, which made milestone progress in Phase III Clinical Study of Project NHT210118.

The NHT210118 Project Kick-off Meeting at the leading organization was hosted by Novel Peptide Bioscience Co., Ltd. and chaired by Prof. Ning Qin from the Department of Infectious Diseases of Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, with the main participants from the medical and clinical operation team of Novel Peptide Bioscience Co., Ltd., team of the Department of Infectious Diseases of Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, directors and secretaries of Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, team of CRO (Shanghai Zenith Medical Research Co., Ltd.) and team of SMO (LinkStart SMO).

This Kick-off Meeting was the first Study Site Kick-off Meeting about Phase III Clinical Study of Project NHT210118. At first, Prof. Ning Qin from the Department of Infectious Diseases chaired the Meeting and introduced the participants; then Zhao Tingting, the medical director of Novel Peptide, delivered the previous study results of the Project; finally, the clinical director of Novel Peptide introduced the Phase III Clinical Protocol of the Project; the participants on site actively delivered speeches and discussions from multiple aspects including the operation difficulty of the Project Protocol, the standardization of the study, the protection of the rights of the subjects, and finally reached a unanimous conclusion, showing their confidence in the development of the Project.